» Articles » PMID: 15592271

Persistence of Human Papillomavirus Infection As a Predictor for Recurrence in Carcinoma of the Cervix After Radiotherapy

Overview
Publisher Elsevier
Date 2004 Dec 14
PMID 15592271
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study was undertaken to examine a possible correlation between clearance or persistence of human papillomavirus (HPV) infection and radiation response in carcinoma of the cervix.

Study Design: We reviewed 97 patients with HPV-positive cervical squamous cell carcinoma (International Federation of Gynecology and Obstetrics [FIGO] stage IB-IVA) treated with radiotherapy. Examination of HPV DNA was performed by the polymerase chain reaction-based assay.

Results: Cervical HPV DNA cleared in 42 patients (43.3%) and persisted in 55 patients (56.7%) at the end of irradiation. All of 42 HPV-cleared patients (100.0%) and 50 of 55 HPV-persistent patients (90.9%) had complete response. Of 92 patients with complete response, 20 (21.7%) had local recurrence develop. The recurrence rate was significantly higher in HPV-persisted patients (34.0%) than in HPV-cleared patients (7.1%) ( P = .0016). Univariate analysis demonstrated the significant differences for both 5-year local disease-free survival (LDFS) and overall survival (OAS) between HPV-cleared and HPV-persisted groups. Multivariate analysis showed that persistence of HPV DNA was the most powerful independent predictor for LDFS and OAS compared with other prognostic factors, such as FIGO stage or node swelling.

Conclusion: In HPV-positive cervical carcinoma, persistence of HPV DNA in the cervix at the end of irradiation was highly predictive of LDFS and OAS.

Citing Articles

Study on the preoperative value of serum SCC-Ag in predicting the stromal invasion of cervical squamous cell carcinoma.

Qin L J Cancer Res Clin Oncol. 2023; 149(11):9167-9171.

PMID: 37184678 DOI: 10.1007/s00432-023-04836-6.


Prediction of carcinogenic human papillomavirus types in cervical cancer from multiparametric magnetic resonance images with machine learning-based radiomics models.

Ince O, Uysal E, Durak G, Onol S, Yilmaz B, Erturk S Diagn Interv Radiol. 2023; 29(3):460-468.

PMID: 36994859 PMC: 10679607. DOI: 10.4274/dir.2022.221335.


A Phase 1 Trial Assessing the Safety and Tolerability of a Therapeutic DNA Vaccination Against HPV16 and HPV18 E6/E7 Oncogenes After Chemoradiation for Cervical Cancer.

Hasan Y, Furtado L, Tergas A, Lee N, Brooks R, McCall A Int J Radiat Oncol Biol Phys. 2020; 107(3):487-498.

PMID: 32151670 PMC: 7705948. DOI: 10.1016/j.ijrobp.2020.02.031.


Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis.

Sabeena S, Kuriakose S, Damodaran B, Ravishankar N, Arunkumar G J Gynecol Oncol. 2020; 31(2):e20.

PMID: 31912676 PMC: 7044009. DOI: 10.3802/jgo.2020.31.e20.


Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol.

Wang Y, Ouyang Y, Su J, Liu J, Cai Q, Xu Q BMJ Open. 2019; 9(10):e028171.

PMID: 31594870 PMC: 6797403. DOI: 10.1136/bmjopen-2018-028171.